{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T13:29:43Z","timestamp":1793626183848,"version":"4.5.1"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Dermatology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clindermatol.2026.09.017","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T23:35:10Z","timestamp":1790033710000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hair and scalp effects of glucagon-like peptide-1 receptor agonists in practice"],"prefix":"10.1016","author":[{"given":"Alina G.","family":"Bridges","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiaranesha","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clindermatol.2026.09.017_bib0001","unstructured":"Food and Drug Administration. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Silver Spring, MD: U.S. Food and Drug Administration; 2026. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/ob\/index.cfm. Accessed October 1, 2026."},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0002","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s40257-026-01021-6","article-title":"The impact of GLP-1 receptor agonists on hair: beneficial effects or adverse outcomes?","volume":"27","author":"Seyed Jafari","year":"2026","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0003","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/ijd.17246","article-title":"GLP-1 agonists and hair loss: a call for further investigation","volume":"63","author":"Desai","year":"2024","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2026.113333","article-title":"Glucagon-like peptide-1 receptor agonists and hair loss: a systematic review and meta-analysis","volume":"237","author":"Cheng","year":"2026","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity [SURMOUNT-5]","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0006","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1111\/jdv.20197","article-title":"Alopecia associated with the use of semaglutide and tirzepatide: a disproportionality analysis using the FDA Adverse Event Reporting System (FAERS) from 2022 to 2023","volume":"39","author":"Godfrey","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0007","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.jaad.2025.01.046","article-title":"Glucagon-like peptide-1 receptor agonist medications and hair loss: a retrospective cohort study","volume":"92","author":"Burke","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0008","doi-asserted-by":"crossref","DOI":"10.1002\/dmrr.70163","article-title":"Not all GLP-1 receptor agonists are alike: real-world evidence of differential endocrine and dermatologic safety","volume":"42","author":"Lee","year":"2026","journal-title":"Diabetes Metab Res Rev"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0009","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","article-title":"Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"402","author":"Knop","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0010","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0011","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0012","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0013","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jaad.2026.03.015","article-title":"Alopecia after glucagon-like peptide-1 agonist therapy: a TriNetX database active comparator retrospective cohort study","volume":"95","author":"Lauck","year":"2026","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0014","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1097\/DSS.0000000000005176","article-title":"The role of glucagon-like peptide-1 receptor agonists in hair loss: clinical evidence and proposed mechanisms","volume":"52","author":"Zarabian","year":"2026","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2026-100077","article-title":"Risk of hair loss associated with glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes: target trial emulation","volume":"394","author":"Tang","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0016","doi-asserted-by":"crossref","DOI":"10.1002\/lary.70810","article-title":"Nonscarring alopecia in adults treated with GLP-1s: a propensity score matched TriNetX cohort study","author":"Katragadda","year":"2026","journal-title":"Laryngoscope"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0017","doi-asserted-by":"crossref","first-page":"11","DOI":"10.36849\/JDD.9448","article-title":"Cutaneous adverse events associated with GLP-1 receptor agonists: a FAERS database analysis from 2018\u20132024","volume":"25","author":"Fat","year":"2026","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0018","unstructured":"Saxenda (liraglutide) injection [prescribing information]. Novo Nordisk Inc. https:\/\/www.google.com\/url?q=https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/206321s025lbl.pdf&source=gmail&ust=1793462021523000&sa=E Accessed October 30, 2026."},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0019","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jdermsci.2021.01.007","article-title":"Telogen effluvium\u2014a review of the science and current obstacles","volume":"101","author":"Chien","year":"2021","journal-title":"J Dermatol Sci"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0020","first-page":"243","article-title":"Hair loss: diagnosis and treatment","volume":"110","author":"Dakkak","year":"2024","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0021","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1001\/jamainternmed.2025.1794","article-title":"Integrating diet and physical activity when prescribing GLP-1s\u2014lifestyle factors remain crucial","volume":"185","author":"Mehrtash","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0022","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.ajcnut.2025.04.023","article-title":"Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and the Obesity Society","volume":"122","author":"Mozaffarian","year":"2025","journal-title":"Am J Clin Nutr"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0023","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamadermatol.2022.4867","article-title":"Evaluation of the safety and effectiveness of nutritional supplements for treating hair loss: a systematic review","volume":"159","author":"Drake","year":"2023","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0024","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-5793(94)01430-9","article-title":"Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences","volume":"358","author":"Wei","year":"1995","journal-title":"FEBS Lett"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0026","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.3390\/jcm15082944","article-title":"Effects of glucagon-like peptide-1 receptor agonists on skin homeostasis and skin aging processes","volume":"15","author":"\u017daliukait\u0117","year":"2026","journal-title":"J Clin Med"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0027","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.regpep.2006.02.007","article-title":"Glucagon-like peptide-1 receptor and proglucagon expression in mouse skin","volume":"134","author":"List","year":"2006","journal-title":"Regul Pept"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0029","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202400653R","article-title":"Dermal white adipose tissue: development and impact on hair follicles, skin defense, and fibrosis","volume":"38","author":"Peng","year":"2024","journal-title":"FASEB J"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jid.2020.12.019","article-title":"Dermal adipose tissue secretes HGF to promote human hair growth and pigmentation","volume":"141","author":"Nicu","year":"2021","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0031","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jaad.2021.11.058","article-title":"Feasibility of adipose-derived therapies for hair regeneration: insights based on signaling interplay and clinical overview","volume":"89","author":"Guo","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0032","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13574","article-title":"GLP-1 analogs and regional adiposity: a systematic review and meta-analysis","volume":"24","author":"Akoumianakis","year":"2023","journal-title":"Obes Rev"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0033","doi-asserted-by":"crossref","first-page":"qdaf381","DOI":"10.1093\/jsxmed\/qdaf381","article-title":"Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes: a systematic review","volume":"23","author":"Deameh","year":"2026","journal-title":"J Sex Med"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0034","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamadermatol.2026.0859","article-title":"The National Psoriasis Foundation primer on GLP-1 receptor agonists in psoriasis: a review","volume":"162","author":"Sheth","year":"2026","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0035","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/j.jaad.2025.04.058","article-title":"GLP-1 agonists may modulate treatment efficacy in central centrifugal cicatricial alopecia","volume":"93","author":"Desir","year":"2025","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0036","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jdcr.2023.05.026","article-title":"Central centrifugal cicatricial alopecia in Black men: a case series highlighting key clinical features in this cohort","volume":"38","author":"Lubov","year":"2023","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0037","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5826\/dpc.0701a01","article-title":"Diet and hair loss: effects of nutrient deficiency and supplement use","volume":"7","author":"Guo","year":"2017","journal-title":"Dermatol Pract Concept"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0038","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/jamadermatol.2024.4593","article-title":"Low-dose oral minoxidil initiation for patients with hair loss: an international modified Delphi consensus statement","volume":"161","author":"Akiska","year":"2025","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0039","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00403-022-02331-5","article-title":"Oral minoxidil use in androgenetic alopecia and telogen effluvium","volume":"315","author":"Feaster","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0040","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40257-025-00990-4","article-title":"Oral minoxidil for alopecia treatment: risks, benefits, and recommendations","volume":"27","author":"Ong","year":"2025","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0041","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1007\/s11695-021-05311-2","article-title":"Hair loss after metabolic and bariatric surgery: a systematic review and meta-analysis","volume":"31","author":"Zhang","year":"2021","journal-title":"Obes Surg"},{"key":"10.1016\/j.clindermatol.2026.09.017_bib0042","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1007\/s11695-025-07903-8","article-title":"Hair loss and metabolic and bariatric surgery: an updated systematic review and meta-analysis","volume":"35","author":"Taghizadeh","year":"2025","journal-title":"Obes Surg"}],"container-title":["Clinics in Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002439?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0738081X26002439?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:54:14Z","timestamp":1793624054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0738081X26002439"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S0738081X26002439"],"URL":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.017","relation":{},"ISSN":["0738-081X"],"issn-type":[{"value":"0738-081X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hair and scalp effects of glucagon-like peptide-1 receptor agonists in practice","name":"articletitle","label":"Article Title"},{"value":"Clinics in Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clindermatol.2026.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}